Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Phase 3
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F)
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- MidLantic Urology
- Target Recruit Count
- 113
- Registration Number
- NCT05799248
- Locations
- 🇺🇸
MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
News
No news found